<DOC>
	<DOCNO>NCT02252341</DOCNO>
	<brief_summary>Effects N-Acetyl-Cysteine patient bipolar depression ( primary outcome Hamilton Depression Rating Scale ) without tobacco use disorder inflammatory oxidative stress biomarkers</brief_summary>
	<brief_title>Efficacy N-Acetyl-Cysteine Bipolar Disorder Tobacco Use Disorder</brief_title>
	<detailed_description>The study subject bipolar depressive patient seek outpatient treatment bipolar affective disorder psychiatric outpatient clinic Heath Unit System Network Outpatient Hospital State University Londrina , tobacco use disorder accord criterion Diagnostic Statistical Manual Mental Disorders , control use never smoker . This placebo-controlled , 12 week , sample 130 bipolar patient seek treatment outpatient clinic Hospital clinical psychiatry State University Londrina clinical trial , double-blind , randomize , May 2015 May 2016 . Patients randomly allocate two group , double-blind , receive combination product ( NAC , 1.8 g/day ) placebo period 12 week . Both group remain receiving maintenance treatment outpatient psychiatry , general medical routinely review psychiatric . The dosage fix 1.8 g /day NAC administer capsule take 1 breakfast , 1 lunch 1 dinner equal dos . The choice dosage base previous study ( Prado et al. , submit ) , similar dos effective well tolerate . To enable process double-blind study medication ( NAC placebo ) dispense monthly number identical formulation package seal pharmacist participate parallel test . Patients blood test assessment oxidative stress baseline randomize use NAC placebo final stage 12 week , new assessment collection blood analysis oxidative stress perform . Clinicians conduct study blind allocation NAC placebo patient . The NAC compound low rate adverse effect , among described diarrhea , nausea dermatological allergy . It consider low risk medication . The placebo basis lactose , compose almost devoid risk side effect except allergic lactose ( exclusion criterion ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>To include study participant 18 65 year , sex , race , capacity consent study carefully follow guideline procedure sign term free inform consent . Patients bipolar depression include score 21 Hamilton Depression Rating Scale ( 17 item ) 14 Beck Depression Inventory . We exclude : patient delirium cognitive deficit failure understanding reflection change . Furthermore , dementia , amnesia cognitive disorder , infectious disease hepatitis B C , HIV , chronic disease renal failure , obstructive pulmonary disease autoimmune interferon treatment , stroke , Parkinson 's disease , pathological use psychoactive substance consumption antioxidant . These situation affect inflammatory / immune process</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>smoking</keyword>
	<keyword>inflammation</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>NAC</keyword>
	<keyword>treatment</keyword>
</DOC>